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Introduction
Studies of fungi have been ongoing for more than 
150  years, beginning with the fi rst mycological paper 
published in 1852 [1,2]. It is only in the past 10  years, 
however, that the microbiome as a novel microbiological 
concept, in which all microbes (bacteria, archaea, viruses 
and fungi) in an enviro nment are taken into account, has 
drawn closer attention [3]. In particular, two large 
government-backed projects launched in the past fi ve 
years  - the Human Microbiome Project (HMP) in the 
United States and Metagenomics of the Human Intestinal 
Tract (MetaHit) in Europe  - have provided progress in 
this new fi eld of research [4-6]. Th ese projects have 
defi ned what constitutes the normal bacterial micro-
biome of various human body sites, such as the oral 
cavity, skin, vagina, and gut. Exciting as the results have 
been, the characterization of fungal diversity in these 
body sites is still lacking. In fact, the word ‘microbiome’ 
has implied reference to only commensal and pathogenic 
bacteria [7]. Th is connotation changed in 2010, when the 
term ‘mycobiome’ (a combination of the words ‘myco-
logy’ and ‘microbiome’) was fi rst used to refer to the 
fungal microbiome [8]. Still, in a recent search of PubMed 
(6  July 2013), the term ‘mycobiome’ appeared in only 
10  publications, and relevant studies  - with or without 
using this specifi c word  - numbered fewer than 40. 
Clearly, this fi eld is still in its infancy.
Th ere are several reasons to include the mycobiome in 
assessments of the biota of specifi c environments. First, 
the incidence of fungal infection has increased greatly in 
the past two decades, primarily in opportunistic 
infections of immunosuppressed populations, such as in 
those who have AIDS or have undergone organ trans-
plantation or cancer chemotherapy [9]. Second, several 
diseases that were formerly considered to have no 
association with fungi, such as hepatitis B [10], cystic 
fi brosis [11,12] and infl ammatory bowel disease (IBD) 
[13,14], are now found to be associated with particular 
mycobiomes. Finally, the interaction between diff erent 
biomes [15], and between the host and the mycobiome 
[16], are critical in disease progression. In this review, we 
summarize the methodology used to study the myco-
biome, its composition and role in health and disease, 
and the outlook for this fi eld.
Tools used to explore the fungal biome
Th e most basic fungal culture technique, dating back to 
the 1920s, involved growing fungal mats in fl asks of 
sterile liquid media. Th e experimental results were 
evaluated by looking at the growth structures and assess-
ing their composition within the media [17]. Fungal 
culture methodology has improved over the decades, but 
even now, organisms that occur in low abundance and 
those that require microbe-microbe interactions to grow 
cannot be cultivated optimally [18].
Like unculturable bacteria in the microbiome, un-
culturable fungi comprise the largest part of the human 
mycobiome. In a study of the bacterial and fungal 
microbiome of patients with cystic fi brosis, more than 
60% of the species or genera were not detected by culture 
[19]. A study focusing on the mycobiome of the oral 
cavity reported that 11 of the 85 fungal genera identifi ed 
could not be cultured [6]. In the gastrointestinal 
mycobiome, culture-independent methods identifi ed 37 
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different fungal groups compared to only 5 species found 
by culture-dependent analyses [10].
The limitations of culture-dependent methods for 
mycobiome studies have led to the introduction, over the 
past 20 years, of culture-independent approaches. Methods 
for classifying fungi that do not rely on microbial culture 
include restriction fragment length polymorphism 
(RFLP) analysis, oligonucleotide fingerprinting of rRNA 
genes (OFRG), denaturing gradient gel electrophoresis 
(DGGE), and in-situ hybridization (Table 1). These tech-
niques are useful for comparing fungal diversities between 
different groups, but they lack the specificity necessary to 
identify the different fungal species in a large-scale study.
Direct sequencing of fungal genes has proven to be the 
most efficient method for classifying the mycobiome. 
Furthermore, with the development of next-generation 
sequencing (NGS) platforms, direct sequencing has 
become more cost-effective than was the case when only 
classical Sanger sequencing was available. Selecting 
target genomic regions to serve as proxy for the full-
length genome is a popular approach for studies of fungal 
diversity, as it is in the determination of bacterial diversity 
in microbiome studies. The fungal ribosomal RNA gene 
cluster (rRNA) is the region most commonly selected as 
proxy, with sequencing efforts primarily targeting the 18S 
small subunit rDNA (SSU), 28S large subunit rDNA 
(LSU) or the internal transcribed spacer (ITS) [20]. 
Although 28S has gradually been eliminated as a target 
sequence because of its lack of discrimination power for 
many species, the debate over whether the 18S or the ITS 
sequences are most useful is still fierce. Compared with 
18S, ITS is more diverse and enables greater genus-level 
phylogenetic placement. However, in our own experience, 
the higher conservation of the 18S facilitates the ampli fi-
cation of rDNA from various fungi, and also enables the 
detection of non-fungal eukaryotes, such as the parasitic 
protozoa Leishmania and Toxoplasma [21,22].
Which region within the ITS is selected as a target also 
remains a matter of choice. Several studies amplify the 
ITS1 or ITS2 regions, whereas others favor amplifying 
the entire length of ITS1-5.8S-ITS2 (Table  2; Figure  1). 
This selection should be made carefully because some 
primers, such as the ITS1 and ITS1-F primers, are biased 
toward amplification of Basidiomycetes, whereas others, 
such as the ITS2 and ITS4 primers, are biased toward 
Ascomycetes [23]. The quantitative evaluation and 
rational design of improved ITS primers are still badly 
needed, and experience gained in the evaluation of 16S 
primer sets for bacterial microbiome studies could 
provide a good model to follow in this endeavor [24]. To 
judge the accuracy of different primer pairs in taxonomic 
classification, it would be worth sequencing the full-
length ITS, trimming it to simulate the different ampli-
cons that would be obtained by various primer pairs, and 
comparing them back with the full-length ITS. Similarly, 
and as has been done for bacterial species [25], it may be 
interesting to construct a ‘mock’ community (MC) with a 
known composition of fungal species, amplify the rDNA 
with various primer pairs, and compare the abundance of 
each species detected with the actual original proportions.
Thus, at present, no common view exists as to the 
single best fungal rDNA region to select for deep-
sequencing analysis. If the goal of the study is to measure 
the abundance of specific fungi, then using the same set 
of primers for each mycobiome included in the study is 
important; but if the intent is to characterize fungal 
diversity, then a combination of different regions would 
probably cover more fungal species and thus produce 
more comprehensive results. Our experience leads us to 
believe that the efficiency of amplification and the size of 
the amplicon generated also dictate which portion is the 
most productive, with shorter amplicons being more 
consistently generated.
Several NGS platforms that vary in their characteristics 
are available for mycobiome sequencing. Despite its 
relatively high cost, pyrosequencing on the Roche/454 
GS-FLX is the method most commonly used in myco-
biome studies because it achieves the longest sequence 
reads (500  bp). Other, newer NGS platforms, including 
Illumina’s HiSeq and MiSeq and Life Technologies’ Ion 
Torrent, have also demonstrated their potential recently. 
Based on results obtained in bacterial microbiome 
studies, the HiSeq platform provides the highest data 
output at the lowest cost (50  times less expensive than 
454 pyrosequencing), whereas MiSeq is more appropriate 
when longer read length and quick turn-around time are 
the priority [26,27]. The Ion Torrent (Ion PGM™ 
Sequencer and Ion Proton™ Sequencer), with its new 
protocols leading to 400  bp sequence reads, has also 
become competitive, providing a low-cost, scalable and 
high-throughput solution [28].
Analysis of sequence data also presents a number of 
issues relating to methodology. First, the pipeline must be 
selected. Two of the most commonly used pipelines in 
the analysis of microbiome sequencing data are QIIME 
(http://qiime.org) and mothur (http://www.mothur.org). 
Built upon a series of bioinformatic tools, both pipelines 
allow: the trimming, screening, and alignment of 
sequences; the assignment of operational taxonomic 
units (OTUs); phylogenetic analyses; and determination 
of fungal diversity within and across groups (referred to 
as α and β diversities) [29,30]. In addition, pipelines that 
are specific for mycobiome studies, such as CloVR-ITS 
and BROCC, have been developed recently [21,31]. A 
database against which the amplified sequences can be 
compared must also be selected, but a database as rich as 
that for bacterial 16S rDNA is still lacking for fungi, as is 
the capability to categorize fungal rRNA sequences at the 
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level of subspecies. Research groups currently use the 
fungal rDNA databases of UNITE (http://unite.ut.ee/), 
which includes 6,816 ITS sequences from 1,977 species 
within 418 genera of fungi [32,33], and SILVA (http://
www.arb-silva.de/), which includes 6,571 18S and 1,753 
28S sequences from fungi in its release 111. Useful as 
these databases are, they do have some limitations that 
affect taxonomic assignments. For example, many 
synonyms and misclassifications are found in the fungal 
nomenclature; and sexual and asexual forms of a fungal 
species can be classified as different taxa [21]. Recently, 
Findley and colleagues optimized the current ITS 
database by fixing many of the inconsistencies described 
in taxonomic entries [22]. They also implemented a 
species-level resolution to skin-associated Malassezia 
within the software pplacer [34], which provides 
phylogenetic place ment of the sequences. Despite these 
advancements, we still need to improve the reliability of 
fungal analyses by pursuing a more systematic evaluation 
of current data bases to determine whether the 
mycobiomes analyzed to date are indeed well 
characterized.
Table 1. Summary of culture-independent methods for studying the mycobiome
Method Procedure Strength Weakness
RFLP [10,60,61] 1.  PCR of rDNA
2.  Build the clone library
3.  Digest with endonucleases
4.  Run capillary electrophoresis
Allow comparisons 
of fungal abundance 
across groups
1.  Considerable intraspecific variability
2.  Not specific enough to differentiate fungi at 
the level of species
3.  Unable to quantify the proportion of each 
type of fungi in the mycobiome
OFRG [62] 1.  PCR of rDNA
2.  Build the clone library
3.  Hybridize with oligonucleotide probes
DGGE [14] 1.  PCR of rDNA
2.  Build the clone library
3.  Run the denaturing gel electrophoresis
4.  Analyze the patterns of the bands
In situ hybridization [14] 1.  Process biopsy sample
2.  Probe hybridization
Sanger sequencing [50] 1.  PCR of rDNA
2.  Build the clone library
3.  Sanger sequencing 
Specific enough to 
differentiate between 
species
High cost [63]
Pyrosequencing [18,64] 1.  PCR of rDNA
2.  Pyrosequencing 
1.  Homo-polymerization
2.  Environmental contamination
Table 2. Summary of primers for fungal rDNA amplification used in mycobiome studies
Amplicon  Primer sets Primer sequence  Length* Citation
ITS  ITS1 ITS1F/ITS2 CTTGGTCATTTAGAGGAAGTAA 260 bp [8,31] 
   GCTGCGTTCTTCATCGATGC  
 ITS2  3271-ITS2F/3271-ITS2R CARCAAYGGATCTCTTGG 340-360 bp [19] 
   GATATGCTTAAGTTCAGCGGGT  
 ITS1-5.8S-ITS2 ITS1F/ITS4 CTTGGTCATTTAGAGGAAGTAA 550 bp [65] 
   TCCTCCGCTTATTGATATGC  
LSU  LROR_F/LR5-F CCGCTGAACTTAAGCATATCAATA 860 bp [65] 
   CGATCGATTTGCACGTCAGA  
  NL1/NL4 GCATATCAATAAGCGGAGGAAAAG 600 bp [66] 
   GGTCCGTGTTTCAAGACGG  
SSU  18S_0067a_deg/NSR 399 AAGCCATGCATGYCTAAGTATMA 350 bp [21] 
   TCTCAGGCTCCYTCTCCGG  
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Composition and role of the mycobiome in health 
and disease
The ultimate aim of human mycobiome studies is to 
uncover the role that fungal populations play in affecting 
health. Unfortunately, owing to the limitation of culture-
dependent methods in mycology, most early studies were 
restricted to the analysis of a few species: Candida 
albicans, Candida glabrata, Cryptococcus neoformans, 
Aspergillus fumigatus and the dimorphic fungi (Coccidi-
oides, Histoplasma and Blastomyces) [9]. The develop-
ment of culture-independent methods has expanded our 
knowledge of the mycobiomes found in different body 
sites and their association with disease (Table  3). For 
example, specific organs that were previously thought to 
be sterile, such as the lung [19], are now known to harbor 
a variety of fungi. In other body sites previously known to 
be colonized with fungus, the fungal variety detected by 
classical methods is much less than that discovered by 
newly developed methods. Figure 2 shows an integrated 
analysis of different myco biomes reported in the litera-
ture. Fungal distributions show significant differences 
among distant body sites, whereas similar patterns of 
distribution were found in mycobiomes from nearby 
sites. For example, Clado sporium species, Aspergillus 
species and Penicillium species all dominate other fungal 
genera in both in both oral and nasal cavities [8,35].
Although the association of many mycobiomes with 
various diseases has been reported, more associations 
will undoubtedly be characterized in the future. For 
example, immune-suppressed (for example, HIV-positive) 
individuals are more likely to contract opportunistic 
fungal (and protozoa) infections than are healthy persons; 
thus, mycobiome studies on immune-suppressed indi-
viduals are needed to uncover more relevant fungal 
species, and possibly to identify the mechanistic link 
between fungal pathogenesis and immune suppression. 
In lung disease, several studies have attempted to charac-
terize the mycobiome in cystic fibrosis (CF) [11,12,19]. 
These studies suggest that the fungal diversity is lower in 
CF patients than in healthy people. The lung mycobiome 
has not yet been determined in those with chronic 
obstructive pulmonary disease (COPD) or asthma, 
although it may have an effect on the progression of these 
conditions [18].
The mycobiomes present in different body sites poten-
tially interact with each other. At present, the gastro-
intestinal-respiratory interaction is understood most 
clearly: a disturbance of the gut mycobiome by 
C.  albicans impacts allergic pulmonary disease induced 
by A.  fumigatus in the lung mycobiome [36]. Trans-
location into the bloodstream and subsequent circulation 
of molecules from fungi, such as RNA, DNA or peptido-
glycans, may initiate systemic immune responses and 
lead to disease remote from the initial site of fungal 
infection [37,38].
Interactions between the mycobiome and the bacterial 
microbiome may also play a role in health and disease 
(Table  4). In some cases, the occurrence of bacteria 
correlates positively with the presence of fungi; for 
example, Mycobacterium superinfection sometimes 
occurs along with aspergillosis [39]. In other cases, 
bacteria compete with fungi; the growth of Candida 
species and possibly other fungi is suppressed when 
Pseudomonas aeruginosa dominates in CF [40]. Various 
hypotheses have been proposed to explain the dual 
nature of this interaction. In the case of Mycobacterium 
and aspergillosis, the commensalism of bacteria and 
fungi may synergistically strengthen their resistance to 
environmental pressure, such as antimicrobial agents 
[41]. In the case of Candida and Pseudomonas, the 
inhibition of fungal growth by the bacteria may better 
meet the nutritional requirements of the bacteria, allow-
ing them to secure more attachment sites on the host cell 
[12]. Regardless of whether the interaction between a 
mycobiome and a bacterial microbiome is synergistic or 
competitive, it has the potential to alter both the intrinsic 
Figure 1. Schematic representation of the fungal ribosomal gene cluster, with binding locations of PCR primers. Within the fungal rDNA, 
18S, 5.8S and 28S are separated by ITS1 and ITS2. Several primer sets that target specific regions of the fungal rDNA have been designed and used 
in previous studies.
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Table 3. Summary of mycobiomes in different body sites
Sequencing method/ 
specimen type Health status 
(sample size (n)) or disease Fungal composition of the mycobiome  Citation
Oral cavity
Pyrosequencing/oral rinse samples 
(n = 20)
Healthy Candida (22.2%), Cladosporium (19.4%), Aspergillus (11.1%), Fusarium (5.6%), 
Glomus (5.6%), Penicillium (4.2%), Alternaria (4.2%), Saccharomycetales (13.9%), 
Cryptococcus (2.8%), Ophiosoma (2.8%), Phoma (2.8%), Schizosaccharomyces (2.8%), 
Zygosaccharomyces (2.8%)
[8]
Culture and morphologic 
observation/oral mucosal swabs 
(n = 30)
AIDS Candida (100%) [67]
Nasal cavity
Culture and morphologic 
observation/nasal mucosal swabs 
(n = 48)
Allergies Cladosporium (29.4%), Penicillium (20.6%), Alternaria (11.7%), Aspergillus (11.7%), 
Rhodotorula (2.9%), Chrysonilia (2.9%), Paecilomyces (5.8%), Stemphylium (2.9%), 
uncultivated Ascomycota (2.9%), Cladophialophora (2.9%), others (2.9%)
[35]
Lung
Pyrosequencing/sputum samples 
(n = 83)
Cystic fibrosis Candida, Saccharomyces, Malassezia, Fuscoporia, Fusarium, Acremonium, 
Thanatephorus, Cladosporium
[12]
Pyrosequencing/sputum samples 
(n = 4)
Candida (74.98%), Neosartorya (16.68%), Malassezia (2.95%), Hyphodontia (1.04%), 
Kluyveromyces (1.02%), Aspergillus (0.93%), Penicillium (0.70%), Peniophora (0.43%), 
Clavispora (0.29%), Piptoporus (0.28%), Dioszegia (0.27%), Phlebiopsis (0.09%), Stereum 
(0.07%), Torulaspora (0.04%), Chalara (0.04%), Physalospora (0.04%), Eurotium (0.03%), 
Cryptococcus (0.03%), Quambalaria (0.03%), Nectria (0.03%), Didymella (0.02%), 
Saccharomyces (0.02%), Sporobolomyces (0.03%), Phaeosphaeria (0.01%), Strobilurus 
(0.01%)
[19]
DGGE/sputum samples (n = 5) Candida dubliniensis, C. albicans, C. parapsilosis, Aspergillus fumigatus [11]
Gut
RFLP/fecal samples (n = 106) Hepatitis B cirrhosis 
and chronic 
hepatitis B
Candida (33.78%), uncultured fungi (12.53%), Aspergillus (7.99%), Simplicillium (5.65%), 
Chaetomium (2.46%), Galactomyces (2.33%), Rhizopus (1.96%), Wallemia (1.10%), 
Fusarium (1.10%), Iodophanus (0.12%), Penicillium (0.49%), Saccharomyces (25.18%), 
uncultured Pezizomycotina (0.86%), uncultured Pucciniomycotina (1.10%), uncultured 
Agaricomycotina (0.74%), Aureobasidium (0.61%), Hyphozyma (0.49%), Asterotremella 
(0.49%), Cryptococcus (0.49%), Doratomyces (0.37%), Ophiocordyceps (0.12%)
[10]
Pyrosequencing/fecal samples 
(n = 10)
Healthy Wallemia, Trichocomaceae, Saccharomycetaceae, Rhodotorula, Pleosporaceae, 
Metschnikowiaceae, Cystofilobasidiaceae, Ascomycota, Amphisphaeriaceae, 
Agaricaceae
[21]
Sanger sequencing/pouch 
endoscopic biopsies (n = 57)
Inflammatory bowel 
disease (including 
Crohn’s disease and 
ulcerative colitis)
Rhodotorula (16.08%), Galactomyces (0.60%), Trametes (9.52%), Pleospora (7.14%), 
Sclerotinia (8.34%), Penicillium (7.74%), Bullera (4.17%), Ustilago (4.17%), Candida 
(2.38%), Chaetomium (2.38%), Flammulina (1.79%), Dacrymyces (1.79%), Exidiopsis 
(1.19%) , Sirococcus (1.19%), uncultured basidiomycete (11.31%), Botryotinia (4.17%), 
Filobasidium (3.51%), Sporolobomyces (2.98%), uncultured ascomycete (2.38%), 
uncultured ustilaginomycete (1.79%), Trichosporon (1.19%), Aureobasidium (0.60%), 
Raciborskiomyces (0.60%), Dothideomycete (0.60%), Cladosporium (0.60%), Madurella 
(0.60%), Tricholoma (0.60%), Graphiola (0.60%)
[14]
Skin
RFLP/limb skin swabs (n = 8) Psoriasis Malassezia, Paracoccidioides, Blastomyces, Histoplasma, Coccidioides, Microsporum, 
Trichophyton, Sporothrix, Trichoderma, Hortaea, Anguillospora, Candida, Pneumocystis, 
Cryptococcus, Trichosporon, Rhodotorula, Rhizopus, Absidia 
[68]
Continued overleaf
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host immune response to pathogens and the suscepti-
bility of the mycobiome and the bacterial microbiome to 
medical therapy.
Interactions between the host and the mycobiome are 
likely to be carefully balanced, leading to clearance, 
asymp tomatic infection, latency, or disease [9]. Several 
factors in the host will have an effect on mycobiome 
composition and variations, including host genotype, 
physiology, immune system, and lifestyle (Figure  3) 
[42,43]. As some of these factors might change over time, 
the mycobiome will fluctuate accordingly. The skin 
mycobiome, for example, is thought to change drastically 
early in life. Using the genotyping of Malassezia species 
as an indicator, one study demonstrated that it takes 30 
days for the skin microbiota to change from its initial 
state to an adult type [44].
The host immune response influences the composition 
of the mycobiome (Figure 4). Several pattern-recognition 
receptors (PRRs) on phagocytes, including TLR-2, TLR-4, 
dectin-1, dectin-2, and galectin-3, specifically recognize 
pathogen-associated molecular patterns (PAMPs) of 
fungi, such as α-mannans, β-mannans, and β-glucans 
[45-48]. Following this pattern recognition, macrophages 
and dendritic cells mature and activate T cells through an 
antigen-presenting process. Depending on which cyto-
kines are stimulated, activated T cells differentiate into 
either Th-1, which promotes the phagocytosis of fungi, or 
Th-2, which activates B cells to release fungi-specific 
antibodies [16]. Two studies also reported the differ-
entiation of Th-17 following C. albicans infection, 
indicat ing a potential role for Th-17 in host defense 
against fungi [47,49]. Despite our depth of knowledge of 
fungal immunology, it remains to be determined whether 
these interactions are ubiquitous or tissue specific, and 
whether some of the interactions mentioned above are 
due entirely to a pathogenic process or are mainly 
involved in retaining the homeostasis required for host 
immune development [7].
Role of the mycobiome: beneficial, commensal or 
pathogenic?
The pathogenesis of many single fungal species has been 
well studied, whereas the correlation between the 
diversity of the whole mycobiome and disease pro-
gression is less clearly defined. It is often assumed that 
fungal diversity should be greater in more severe cases of 
a disease. For some conditions, such as in inflammatory 
bowel disease (IBD) [14], atopic dermatitis [50], and 
hepatitis B cirrhosis or chronic hepatitis B, the diversity 
of fungi present is proportional to the progression of 
disease [10]. But in other disease environments, such as 
the respiratory mycobiome in cystic fibrosis [12,19] and 
the nasal mycobiome in allergic patients [35], the fungal 
diversity is inversely proportional to disease progression 
[35]. To further complicate the issue, the diversity of 
fungi identified in some diseases has no correlation with 
Table 3. Continued
Sequencing method/ 
specimen type Health status 
(sample size (n)) or disease Fungal composition of the mycobiome  Citation
Sanger sequencing/face skin swabs 
(n = 9)
Atopic dermatitis Malassezia (67.9%), Cladosporium (5.5%), Candida (5.2%), Cryptococcus (5.2%), 
Rhodotorula (4.0%), Trichosporon (2.6%), Meyerozyma (2.0%), Alternaria (1.9%), 
Debaryomyces (0.3%), Phialophora (0.3%), Aspergillus (0.2%), Davidiella (0.1%), Mrakia 
(0.1%), Wallemia (0.1%), Sporobolomyces (0.2%), Penicillium (0.2%), Saccharomyces 
(0.1%), Sympodiomycopsis (0.1%), Tilletiopsis (0.1%), Apioplagiostoma (0.1%), 
Toxicocladosporium (1.5%), Wickerhamomyces (0.7%), Aureobasidium (1.9%), Exophiala 
(0.1%), Gibellulopsis (0.1%), Persiciospora (0.1%), Trametes (0.1%)
[50]
Pyrosequencing/scalp swabs (n = 7) Dandruff-afflicted 
scalps
Filobasidium (33.85%), Penicillium (3.44%), Malassezia (1.91%), Eupenicillium (0.04%), 
Acremonium (57.91%), uncultured soil fungus (2.47%), Cryptococcus (0.26%), 
Didymella (0.05%), Rhodotorula (0.05%), Coniochaeta (0.00%), uncultured Ascomycete 
(0.02%)
[66]
Culture and morphologic 
observation/foot skin swabs (n = 129)
Foot disease in 
soccer athletes
Trichophyton (76.4%), Candida (20.0%), others (3.6%) [69]
Vagina
Pyrosequencing/vaginal mucosal 
swabs (n = 494)
Healthy Candida (34%), Pichia (2%), Eurotium (1%), Alternaria (1%), Rhodotorula (1%), 
Cladosporium (2%), Davidiellaceae (3%), uncultured Saccharomycetales (6%), 
uncultured Epicoccum (1%), other minorities (49%)
[63]
Conjunctiva
Culture and morphologic 
identification/conjunctiva swabs 
(n = 61)
Leprosy (Hansen’s 
disease)
Candida (26.67%), Aspergillus (13.33%), Geotrichum (6.67%), Acremonium (6.67%), 
Alternaria (6.67%), Chaetonium (6.67%), Drechslera (6.67%), Penicillium (13.33%), 
Cladosporium (6.67%), Phialophora (6.67%) 
[70]
Cui et al. Genome Medicine 2013, 5:63 
http://genomemedicine.com/content/5/7/63
Page 6 of 12
disease status, and the diversity of fungi in samples cluster 
more according to individuals rather than to health status 
[51]. Drawing a generalized conclusion about the 
correlation between diseases and fungal diversity is, thus, 
diffi  cult. Fungal diversity is more likely to correlate 
positively with disease status in those with infectious 
diseases because fungi can exacerbate the infection; in 
chronic diseases, where fungal infection plays a secondary 
role in disease pathogenesis, however, an inverse corre-
lation between fungal diversity and disease progression is 
more likely to occur because the microenvironment (such 
as that resulting from mucus dysfunction in CF) becomes 
less suitable for fungal growth.
Like the mycobiome as a whole, individual members of 
the mycobiome may also play a benefi cial or commensal 
role in the host. Benefi cial fungi have been found to be 
preventive and therapeutic agents, an example being the 
use of Saccharomyces boulardii for the treatment of 
diarrhoeal diseases [52]. Commensal fungi, such as 
Malassezia spp. and C.  albicans, usually co-evolve with 
the adaptive immune system, although in certain cases 
they may switch from a ‘friendly’ relationship with the 
host to a pathological one [53].
Alterations in the mycobiome are frequently reported 
to be associated with disease progression, but it remains 
to be elucidated whether this variation is cause or eff ect. 
One concern is whether such an alteration in the 
mycobiome is primary or secondary to an imbalanced 
bacterial microbiome, as Ott et al. [14] proposed for the 
increase in mycobiome diversity of IBD. A causal 
relationship could be established if an antimicrobial 
treatment targeting certain fungal groups were to lead to 
either exacerbation of disease or cure; on the other hand, 
if the treatment of the disease were to lead concurrently 
to modulation of the mycobiome, then it would seem 
more likely that the mycobiome is being aff ected by the 
disease status [54]. Specifi c mycobiome patterns may be 
useful as diagnostic or prognostic markers of diseases.
Outlook
Targeting vital fungal species that are associated with 
disease progression may impact disease severity. Evidence 
exists to indicate that altering the mycobiome with anti-
fungal drugs can improve certain conditions, such as 
gastro intestinal graft-versus-host disease (GI-GVHD) 
[49]. Furthermore, specifi cally controlling the growth of 
Figure 2. Distribution of fungal genera in diﬀ erent body sites. Fungal distributions diff er signifi cantly among distant body sites, whereas similar 
patterns are found in nearby sites. For example, Cladosporium spp., Aspergillus spp., and Penecillium spp. all dominate other fungal genera in both 
oral and nasal cavities.
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less desirable fungal species, or controlling biofilm-
associated infections, may also be useful in manipulating 
the complex microflora in diseased body sites [19]. 
Another viable alternative to direct antimicrobial treat-
ment is to introduce prebiotic and probiotic therapy to 
restore bacterial commensals. A clinical trial of VSL#3 in 
pouchitis patients showed that the bacterial diversity in 
the gut was increased while the fungal diversity was 
reduced with the use of a probiotic therapy. This effect 
could result from the restoration of the integrity of a 
‘protective’ intestinal mucosa-related microbiota [13].
With a better understanding of the mechanisms of 
recognition and modulation in the immune response to 
fungi, it might become practical to administer immune 
therapy to treat mycobiome-associated diseases. Effective 
monoclonal antibodies, which promote opsonization in 
phagocytosis, activate the complement system or act 
directly on fungal cells [55], have already been developed 
for several fungal species, such as Cryptococcus neo for-
mans [56], C. albicans [57], Histoplasma capsulatum [58] 
and A.  fumigatus [59]. Fungal-targeted vaccination is 
another alternative, in both prophylaxis and therapeutics. 
Fungi that induce a long-term immunity are considered 
better candidates for vaccination [55], and a few vaccines 
have already been put forward for clinical trials, such as 
the killed spherule vaccine against coccidioidomycosis [53].
The limitation of today’s immune therapies is that most 
target only a single fungal species, ignoring the overall 
mycobiome composition. To date, our knowledge of the 
mycobiome suggests that interactions among fungi 
within an environment and between mycobiomes found 
in different body sites may play an important role in 
pathogenesis, and that the development of a broad-
spectrum monoclonal antibody or a universal vaccine 
targeting multiple pathogenic fungi would be more 
promising than therapies targeting a single fungal 
species. Given that many fungi share a series of PAMPs, 
it should be feasible to develop a universal immune 
therapeutic tool that targets such a widely used fungal 
signature.
Along with the heterogeneity of the mycobiome, 
genetic polymorphism across human populations also 
raises different risks for mycobiome-associated diseases 
(summarized by Romani [53]). For instance, the dectin-1 
single nucleotide polymorphism (SNP) Y238X mutation 
could increase the likelihood of Candida colonization 
and indirectly associate with GVHD [49]. With these 
recent findings, the significance of sequencing the 
genomes of hosts with or without disease has been high-
lighted, and personalized treatment is now often touted 
as the way forward. Potentially, by classifying people by 
known genetic markers, we will be able to stratify 
Table 4. Interaction between the mycobiome and bacterial microbiome
  Positive or 
Mycobiome Bacterial microbiome  negative correlation Body sites; disease Citation
Aspergillus spp.
Blastomyces spp.
Mycobacterium spp. Positive Lung; aspergillosis [39]
Candida spp. Staphylococcus epidermidis
Staphylococcus aureus
Pseudomonas aeruginosa
Enterococcus spp. 
Positive Not applicable; implant- and 
catheter-related infections
[71]
Fusobacterium nucleatum
Fusobacterium periodontium
Fusobacterium sulci
Streptococcus gordonii
Streptococcus mutans
Positive Oral cavity; healthy [72-74]
Lactobacillus acidophilus
Lactobacillus casei
Negative Intestine; systematic candidiasis [75]
Lactobacillus spp. Negative Female reproductive tract; 
fungal vulvovaginitis
[76]
Candida spp.
Torulopsis glabrata
Saccharomyces cerevisiae
Aspergillus fumigatus
Pseudomonas aeruginosa
Pseudomonas cepacia
Negative Lung; CF [40]
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Figure 3. Host and environmental factors that contribute to diversity observed in the human mycobiome.
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Figure 4. Interaction between the mycobiome and the immune system. Several pattern recognition receptors (PRRs) on phagocytes 
specifically recognize the pathogen-associated molecular patterns (PAMPs) of fungi. Following this pattern recognition, macrophage and dendritic 
cells mature and activate T cells through an antigen-presenting process. Activated T cells differentiate into either Th-1, which promotes the 
phagocytosis of fungi, or Th-2, which activates B cells to release fungi-specific antibodies, depending by which cytokines they are stimulated. IFN, 
interferon; IL, interleukin; TNF, tumor necrosis factor. (Figure design inspired by the information reported in [16] and [53].)
Macrophage and
Dendritic cell 
PRR
PAMP
Th-2 cell
Th-1 cell
IL-12, IL-23
IL-4, IL-10
B cell
IgM
IgG, IgA
IL-4, IL-5
IFN-γ,TNF-α
Mycobiome
Epithelium
Neutrophil
PRR
PAMP
Complement
system
Cui et al. Genome Medicine 2013, 5:63 
http://genomemedicine.com/content/5/7/63
Page 9 of 12
patients with a high susceptibility to fungal infection, and 
those who would benefit from antifungal agents, thereby 
optimizing the therapeutic effect and reducing the risk of 
antifungal resistance.
Conclusions
Defining the mycobiome has broadened the scope of 
human microbiome studies. Several mycobiomes in 
different body sites have been characterized, and diverse 
mycobiome patterns associated with various diseases. 
After summarizing the methods used in mycobiome 
studies and analyzing the role of the mycobiome in health 
and disease, we propose that combining fungal charac-
ter ization with a generalized assessment of the micro-
biome will expand our understanding of the microbial 
environment in disease progression. The mycobiome 
contributes to disease through the interaction between 
different biomes as well as through the interaction 
between the mycobiome and the host. Future studies 
characterizing the mycobiome will be instrumental in 
understanding disease pathogenesis and in developing 
novel therapies.
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